Hologic gets CE Mark for fusion transplant pathogen tests

2022 04 29 18 14 4601 Hologic Rsna 2019 400

Hologic has announced that it has received the CE Mark for two new molecular assays that monitor for Epstein-Barr virus (EBV) and BK virus (BKV) in transplant patients.

Panther Fusion EBV Quant Assay and Panther Fusion BKV Quant Assay quantify the viral load of the respective viruses with the aim to aid in the diagnosis and management of solid organ transplant patients and hematopoietic stem cell transplant patients.

The in vitro nucleic acid amplification tests run on Hologic's automated Panther Fusion system using real-time PCR technology. The EBV assay is validated for use with whole blood and plasma samples, and the BKV assay is validated for use with human plasma and urine samples.

Page 1 of 11
Next Page